2026-04-17T02:45:10Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/65052025-10-24T10:21:09Zcom_2072_378070com_2072_378040col_2072_378092

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months de las Heras, Begoña Boyle, Frances Ades, Felipe Bozovic Spasojevic, Ivana Capelan Rodríguez, Marta Saini, Kamal S. de Azambuja, Evandro Càncer - Tractament COVID-19 (Malaltia) DISEASES::Neoplasms Other subheadings::Other subheadings::/therapy DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapies, Investigational ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::/terapia ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamientos en investigación Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Càncer; Immuno-oncologia Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cáncer; Inmuno-oncología Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cancer; Immuno-oncology The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a higher proportion have an underlying diagnosis of cancer than seen in the general population. Also, patients with malignancy are likely to be more vulnerable than the general population to contracting COVID-19. Mortality is significantly higher in patients with both cancer and COVID-19 compared with the overall COVID-19-positive population. The early months of the pandemic saw a decrease in cancer screening and diagnosis, as well as postponement of standard treatments, which could lead to excess deaths from cancer in the future. No funding was received from any source. No Rapid Service Fee was received by the journal for the publication of this article. 2025-10-24T10:21:09Z 2025-10-24T10:21:09Z 2025-10-24T10:21:09Z 2021-11-05T11:36:58Z 2021-11-05T11:36:58Z 2020-12 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/6505 Oncology And Therapy;8 https://doi.org/10.1007/s40487-020-00124-2 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess Springer Scientia